JRSIS Health Care Corporation (JRSS) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören JRSIS Health Care Corporation (JRSS), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 35/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026JRSIS Health Care Corporation (JRSS) Sağlık ve Boru Hattı Genel Bakışı
JRSIS Health Care Corporation, based in Harbin, China, operates Jiarun Hospital, offering diverse medical services such as pediatrics, dermatology, and traditional Chinese medicine. With 950 beds, the hospital serves the Heilongjiang Province. The company faces challenges with negative profitability and operates in a competitive healthcare market.
Yatırım Tezi
Investing in JRSIS Health Care Corporation presents a high-risk, high-reward scenario. The company operates in the growing Chinese healthcare market but faces significant challenges. Key value drivers include potential expansion of services and increased patient volume at Jiarun Hospital. However, the company's negative profit margin of -47.0% raises concerns about its financial sustainability. Growth catalysts include potential government healthcare reforms and increased demand for medical services in the Heilongjiang Province. The company's ability to improve operational efficiency and reduce costs is crucial for achieving profitability. Potential investors should carefully consider the risks associated with investing in an OTC-listed company with limited financial information and negative earnings. The company's beta of -0.63 suggests a low correlation with the overall market.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- JRSIS Health Care Corporation operates Jiarun Hospital, a 950-bed facility in Harbin, China.
- The company offers a wide range of medical services, including pediatrics, dermatology, and traditional Chinese medicine.
- The company's profit margin is -47.0%, indicating significant financial challenges.
- The company's P/E ratio is -0.49, reflecting its negative earnings.
- The company's gross margin is 15.3%.
Rakipler & Benzerleri
Güçlü Yönler
- Comprehensive range of medical services.
- Relatively large hospital capacity (950 beds).
- Established presence in Harbin, Heilongjiang Province.
Zayıflıklar
- Negative profit margin (-47.0%).
- Limited geographic diversification.
- OTC listing may limit access to capital.
Katalizörler
- Ongoing: Potential government healthcare reforms in China could benefit private healthcare providers.
- Upcoming: Expansion of medical services at Jiarun Hospital could attract more patients.
- Ongoing: Increased demand for healthcare services in the Heilongjiang Province due to an aging population.
Riskler
- Ongoing: Negative profit margin (-47.0%) raises concerns about financial sustainability.
- Potential: Intense competition from other hospitals and clinics in the region.
- Potential: Regulatory changes impacting healthcare operations in China.
- Potential: Economic downturn affecting patient affordability and demand for services.
- Ongoing: OTC listing and limited financial disclosure increase investment risk.
Büyüme Fırsatları
- Expansion of Medical Services: JRSIS Health Care Corporation can expand its range of medical services to attract more patients and increase revenue. This could involve adding new specialties, such as cardiology or oncology, or investing in advanced medical equipment. The market for specialized medical services in China is growing rapidly, driven by increasing healthcare awareness and rising incomes. Timeline: 2-3 years. Market Size: The Chinese healthcare market is projected to reach $2.3 trillion by 2030.
- Increased Patient Volume: JRSIS Health Care Corporation can increase patient volume at Jiarun Hospital by improving its marketing and outreach efforts. This could involve advertising in local media, partnering with local businesses, and offering discounts and promotions. The demand for medical services in the Heilongjiang Province is growing due to an aging population and increasing urbanization. Timeline: Ongoing. Market Size: The number of hospital visits in China is projected to increase by 5% annually over the next decade.
- Strategic Partnerships: JRSIS Health Care Corporation can form strategic partnerships with other healthcare providers, such as hospitals, clinics, and pharmaceutical companies. This could involve sharing resources, co-marketing services, and developing new products and services. Strategic partnerships can help JRSIS Health Care Corporation expand its reach, improve its efficiency, and enhance its competitiveness. Timeline: 1-2 years. Market Size: The market for healthcare partnerships in China is estimated to be worth $10 billion annually.
- Government Healthcare Reforms: The Chinese government is implementing healthcare reforms to improve access to healthcare and reduce costs. These reforms could create new opportunities for JRSIS Health Care Corporation, such as increased government funding for hospitals and new regulations that favor private healthcare providers. Timeline: Ongoing. Market Size: The Chinese government is investing billions of dollars in healthcare infrastructure and services.
- Telemedicine Integration: JRSIS Health Care Corporation can integrate telemedicine into its operations to reach more patients and improve its efficiency. This could involve offering online consultations, remote monitoring, and virtual care services. The market for telemedicine in China is growing rapidly, driven by increasing internet penetration and the rising demand for convenient healthcare services. Timeline: 1-2 years. Market Size: The Chinese telemedicine market is projected to reach $20 billion by 2025.
Fırsatlar
- Expanding medical services to meet growing demand.
- Leveraging government healthcare reforms.
- Forming strategic partnerships with other healthcare providers.
Tehditler
- Intense competition from other hospitals and clinics.
- Regulatory changes impacting healthcare operations.
- Economic downturn affecting patient affordability.
Rekabet Avantajları
- Established presence in the Heilongjiang Province.
- 950-bed hospital capacity provides a significant infrastructure base.
- Broad range of medical services offers a comprehensive healthcare solution.
JRSS Hakkında
Founded in 2006, JRSIS Health Care Corporation, formerly known as China Runteng Medical Group Co., Ltd, is a healthcare provider operating in Harbin, Heilongjiang Province, China. The company's primary asset is Jiarun Hospital, a 950-bed facility offering a broad spectrum of medical services. These services encompass pediatrics, dermatology, ears, nose, throat, traditional Chinese medicine, ophthalmology, internal medicine, dentistry, general surgery, rehabilitation science, gynecology, and general medical services. JRSIS Health Care Corporation aims to provide comprehensive healthcare solutions to the local population. The hospital is equipped to handle a wide range of medical needs, from routine check-ups to specialized treatments. The company changed its name in November 2013, reflecting its commitment to the healthcare sector. The company's operations are concentrated within the Heilongjiang Province, making it a regional player in the Chinese healthcare market. JRSIS Health Care Corporation faces challenges related to profitability, as indicated by its negative profit margin.
Ne Yaparlar
- Operates Jiarun Hospital, a 950-bed medical facility.
- Provides pediatric medical services.
- Offers dermatological treatments.
- Specializes in ear, nose, and throat care.
- Practices traditional Chinese medicine.
- Provides ophthalmology services.
- Offers internal medicine and dentistry.
- Performs general surgery and rehabilitation science.
İş Modeli
- Generates revenue through patient fees for medical services.
- Receives payments from insurance companies and government healthcare programs.
- Offers a range of medical specialties to attract a diverse patient base.
Sektör Bağlamı
JRSIS Health Care Corporation operates within the Chinese healthcare market, which is experiencing significant growth due to an aging population and increasing healthcare awareness. The market is competitive, with both public and private hospitals vying for patients. Key trends include the increasing adoption of telemedicine and the growing demand for specialized medical services. JRSIS Health Care Corporation's position within this market is challenged by its negative profitability and limited geographic reach. Competitors include other healthcare providers in the Heilongjiang Province and national hospital chains.
Kilit Müşteriler
- Residents of Harbin and the Heilongjiang Province seeking medical care.
- Patients requiring specialized medical treatments.
- Individuals covered by health insurance plans.
Finansallar
Grafik & Bilgi
JRSIS Health Care Corporation (JRSS) hisse senedi fiyatı: Price data unavailable
Son Haberler
JRSS için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
JRSS için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
JRSS için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, JRSS'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Linhai Zhu
CEO
Information on Linhai Zhu's specific background and career history is not available. As the CEO of JRSIS Health Care Corporation, Linhai Zhu is responsible for managing the company's overall operations and strategic direction. The CEO oversees a team of 36 employees and is accountable for the financial performance of Jiarun Hospital. Further details about Linhai Zhu's educational qualifications and previous roles are currently unknown.
Sicil: Due to limited information, it is difficult to assess Linhai Zhu's specific achievements and strategic decisions as CEO. The company's negative profit margin suggests ongoing challenges in achieving profitability. However, without more data, it is impossible to provide a comprehensive evaluation of Linhai Zhu's leadership and impact on the company's performance.
JRSS OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that JRSIS Health Care Corporation may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to regular reporting requirements with the SEC, unlike companies listed on major exchanges like the NYSE or NASDAQ. This tier is considered the most speculative due to the lack of stringent listing standards and oversight.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and liquidity can lead to significant price volatility.
- OTC Other tier companies are subject to less regulatory oversight, increasing the potential for fraud or mismanagement.
- The company's negative profit margin raises concerns about its financial sustainability.
- Potential delisting from the OTC market could further reduce liquidity and value.
- Verify the company's registration and legal standing.
- Attempt to obtain audited financial statements, even if not publicly available.
- Research the background and experience of the company's management team.
- Assess the company's competitive position within the Chinese healthcare market.
- Understand the company's revenue model and cost structure.
- Evaluate the company's ability to improve its financial performance.
- Consult with a qualified financial advisor before investing.
- Operation of a 950-bed hospital suggests a substantial physical presence.
- Provision of a range of medical services indicates a functioning business.
- Company has been in operation since 2006.
JRSS Healthcare Hisse Senedi SSS
JRSS için değerlendirilmesi gereken temel faktörler nelerdir?
JRSIS Health Care Corporation (JRSS) şu anda yapay zeka skoru 35/100, düşük puanı gösteriyor. Temel güçlü yan: Comprehensive range of medical services.. İzlenmesi gereken birincil risk: Ongoing: Negative profit margin (-47.0%) raises concerns about financial sustainability.. Bu bir finansal tavsiye değildir.
JRSS MoonshotScore'u nedir?
JRSS şu anda MoonshotScore'da 35/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
JRSS verileri ne sıklıkla güncellenir?
JRSS fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler JRSS hakkında ne diyor?
JRSS için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
JRSS'a yatırım yapmanın riskleri nelerdir?
JRSS için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Negative profit margin (-47.0%) raises concerns about financial sustainability.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
JRSS'ın P/E oranı nedir?
JRSS için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için JRSS'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
JRSS aşırı değerli mi, yoksa düşük değerli mi?
JRSIS Health Care Corporation (JRSS)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
JRSS'ın temettü verimi nedir?
JRSIS Health Care Corporation (JRSS) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited information available on OTC-listed companies.
- Financial data may not be up-to-date or audited.